Portal portfolio company, Moonlight Therapeutics launches its first-in-human Phase I clinical trial
Share
A significant milestone for our Atlanta-based portfolio company, Moonlight Therapeutics as the company launches its first-in-human Phase I clinical trial evaluating MOON101 for peanut allergy.
Stay up-to-date on the latest VC, biotech, and med tech news in Chicago and across the U.S. Sign up with your email address below to get our monthly newsletter delivered to your inbox!